Department of Radiology, Northwestern Memorial Hospital, Northwestern University-Feinberg School of Medicine, Chicago, IL 60611, USA.
AJR Am J Roentgenol. 2011 Jul;197(1):18-27. doi: 10.2214/AJR.11.6581.
Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy.
Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.
尽管传统的解剖影像学生物标志物，包括世界卫生组织（WHO）标准和实体瘤反应评估标准（RECIST），具有一定的效果，但仍存在局限性。本文将讨论评估肿瘤对治疗反应的传统和新型形态影像学生物标志物。
应用评估肿瘤对治疗反应的既定方法可以使图像解释保持一致性，并促进与肿瘤学家的沟通。由于新的治疗方法，需要将坏死评估和体积信息纳入基于大小的标准中。
